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ABSTRACT.
Purpose: Vitreoretinal (VR) surgery is the third most common intraocular
surgery after refractive and cataract surgery. The impact of statin therapy on
VR surgery outcomes remains unclear, despite a potentially beneﬁcial eﬀect. We
explored the association of preoperative statin therapy and the need for
revitrectomy after primary vitrectomy.
Methods: Our historical, population-based, register-based, VR surgery cohort
consisted of 5709 patients operated in a tertiary, academic referral hospital in
Finland, during 2008–2014, covering 6.5 years.Subgroup analysis was performed
as follows: eyes operated due to (i) rhegmatogenous retinal detachment (RRD), (ii)
VR interface diseases (macular pucker/hole), (iii) diabetic maculopathy or
proliferative retinopathy, (iv) vitreous haemorrhage, (v) lens subluxation, (vi)
vitreous opacities or (vii) other VR indication.The primary end-point event was
revitrectomy during a postoperative follow-up period of 1 year due to retinal
redetachment, vitreous rehaemorrhage, postoperative endophthalmitis, recurrent
pucker or unclosed macular hole.
Results: Rhegmatogenous retinal detachment (RRD) was the second most
frequent indication of VR surgery, including 1916 patients, with 305 re-
operations with rate 0.20 (95% CI 0.18–0.23) per person-year. Statin treatment
in time of operation was associated with lower risk of re-operation according to
relative scale (incidence rate ratio 0.72, 95% CI 0.53–0.97), but not in absolute
scale (incidence rate diﬀerence 0.58, 95% CI 4.30 to 3.15 for 100 person-
years). No association with statin therapy and vitrectomy outcome was observed
in the other VR subgroups.
Conclusion: Use of statin treatment was associated with a 28% lower risk of
revitrectomy in patients operated due to RRD. Further randomized clinical trials
are highly warranted.
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Introduction
Many sight-threatening, posterior seg-
ment, eye diseases can only be treated
with vitreoretinal (VR) surgery. It is the
third most common intraocular surgery
performed after refractive and cataract
surgery in the United States and is
required in 30 per 100 000 population
in UK (El-Amir et al. 2009). Vitreoret-
inal (VR) surgery has a steeper learning
curve and relatively high complication
rate compared to cataract surgery
(Wong et al. 2013). During the past
two decades, great technological
advances in pars plana vitrectomy
(PPV) have been achieved, including
the availability of new microincisional
vitrectomy technology, wide-angle
microscope viewing systems, periopera-
tive optical coherence tomography
imaging, pharmacologic chromovitrec-
tomy and therapeutic agents (Gonzalez
et al. 2015; Khan et al. 2016; Sharma
et al. 2016). Novel 23, 25 and 27 small-
gauge instrumentation with valved
microcannulas, high-speed cutting rates
(from 7500 up to 10 000 cuts per min-
ute), use of preoperative applications of
anti-angiogenic therapy and intra-
operative chromo-assisted vitrectomy
have (i) reduced surgical time, (ii)
decreased surgical vitrectomy complica-
tions and (iii) increased surgical out-
comes. Despite these advances, some
VR patients nevertheless need to be
re-operated, sometimes with poor
functional and anatomical outcome. Of
note, re-operation rates vary between
diﬀerent VR surgical indications.
Statins, 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase
inhibitors, are one of the most com-
monly used drugs worldwide, with a
generally favourable safety proﬁle,
representing evidence-based medica-
tion in primary and secondary preven-
tion of coronary artery disease (Leung






protective pleiotropic properties, ren-
dering them as potential therapeutic
adjuvants in controlling photorecep-
tor survival, the retinal wound-healing
process and inﬂammation-related pro-
liferative vitreoretinopathy (PVR) for-
mation in eyes after VR surgery (Koh
2000; Takemoto & Liao 2001; Kawa-
hara et al. 2008; Kita et al. 2008;
Marcus et al. 2012).
Intraocular ﬁbrosis formation, that
is PVR, ﬁrst reported in 1934 by
Gonin, is a condition considered to be
the worst-case scenario after VR sur-
gery leading to need of re-operation
(Sun et al. 2012; Soni et al. 2013; Claes
& Lafeta 2014). Proliferative vitreor-
etinopathy (PVR) progression involves
inﬂammatory and ischaemic processes,
for which there is no known preventa-
tive pharmacotherapy (Chaudhary
et al. 2016). Historically, many phar-
macologic agents have been studied,
including steroids, daunorubicin, anti-
inﬂammatory, anti-VEGF agents and
5-ﬂuorouracil (Pastor 1998; Moysidis
et al. 2012; Pennock et al. 2013;
Gagliano et al. 2015; Khan et al.
2015). Nonetheless, all of these com-
pounds have failed to demonstrate a
signiﬁcant beneﬁt in clinical VR trials.
The use of statin in ophthalmic surgery
has been shown to be beneﬁcial, par-
ticularly after glaucoma ﬁltration sur-
gery in a rabbit model. Histologic
analyses have revealed decreased
inﬂammatory response and reduced
ﬁbrosis in the statin-treated group
when compared with control group
(Park et al. 2016). More recently, statin
therapy was found to be beneﬁcial also
in VR surgery (Tuuminen et al. 2014,
2015, 2016).
Our aim was to examine whether
systemic use of statin medication could
prevent postoperative complications in
a diverse range of vision-threatening
posterior segment eye diseases and
reduce the need for revitrectomies.
Statins are currently widely used in
many VR patients, but no population-
based large-scale systematic studies of
statin use and outcome of VR surgery
have yet been published. Our main
hypothesis was that use of statin med-
ication might reduce the risk of re-
operations based on the ﬁndings of our
previous studies involving diﬀerent VR
pathologies (Tuuminen et al. 2014,
2015, 2016).
Patients and Methods
Study design and cohort
This study was based on a nationally
representative sample of 5796 VR
patients aged 18 years or over, operated
in a tertiary academic referral VR surgi-
cal unit, Helsinki University Hospital in
Finland, covering 1.6 million of the total
Finnish population of approximately 5.5
million inhabitants. The clinical and
surgical data were collected from all
vitrectomized VR-study patients
between 12 May 2008 and 31 December
2014, covering altogether 6.5 years.
After exclusions (Fig. 1), the ﬁnal study
population comprised 5707patients. The
exclusion criteria are given in Fig. 1.
Data sources and collection
Patient documentation was selected
anonymously and included register
data from three diﬀerent registers
including treating institution Helsinki
University Hospital, Social Insurance
Institution and Statistics Finland (SF),
linked by means of the unique personal
identiﬁcation number assigned to all
people living in Finland.
The baseline data collected from the
hospital operating room management
system (OPERA; GE Healthcare,
Helsinki, Finland) database consisted of
the VR surgical procedure or patient-
related variables, the mode of admission
(day surgery/inpatient stay/emergency)
and the main indications for VR surgery
(International Classiﬁcation of Diseases
(ICD10) code [(http://urn.fi/URN:NBN:
ﬁ-fe201205085423), as follows: (i) eyes
operated due to rhegmatogenous retinal
detachment (RRD), H33.0, n = 1916)];
(ii) VR interface diseases (macular pucker
ormacular hole, H35.38/H35.37/H35.39,
n = 2207; (iii) diabetic retinopathy (DR)
(diabetic maculopathy and proliferative
DRH36.01,H36.03,E10.3,E10.7,E10.9,
E11.3; n = 184); (iv) vitreous haemor-
rhage (H43.1, n = 400); (v) lens subluxa-
tion (H27.1, n = 120); (vi) vitreous
opacities (H43.2, H43.3, H43.9, H43.8;
n = 52); and (vii) individuals who were
operated due to other VR reasons such as
retinal vein occlusion (H34.8 andH34.9),
central serous retinopathy, exudative
maculopathy (H35.31)or variousunspec-
iﬁed reasons were included into the cat-
egory ‘other’ (n = 830) in the ﬁnal
analysis.
The primary VR surgical procedure
was recorded as follows http://urn.fi/
URN:ISBN:978-952-245-858-2 (in Fin-
nish and Swedish): vitrectomy through
pars plana (CKD91; VIT); combined
vitrectomy and retinal procedure
(CKD92; VITRET); combined
Fig. 1. Flow chart of the study population.
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procedure on vitreous body and retina
including encircling scleral buckle (SB)
or band (CKD93; SBVIT); and com-
bined phacoemulsiﬁcation and intrao-
cular lens (IOL) implantation together
with PPV (CKD94; PHACOVIT).
Accordingly, operation day and month,
duration of anaesthesia and surgical
procedure, as well as patient character-
istics (age, gender, height, weight and
body mass index [BMI], and the Amer-
ican Society of Anesthesiologists [ASA]
Physical Status classiﬁcation) were
recorded.
Systemic diseases and concomitant
medication were obtained from the
Social Insurance Institution database.
Information of the following systemic
and ocular diseases was collected: dia-
betes (code 103), kidney disease with
dialysis (137), hypothyreosis (104),
transplantation (127), psychiatric and
other mental illnesses (112), chronic
heart disease (201), connective tissue
disease, rheumatic diseases and other
related conditions (202), chronic hyper-
tension (205), coronary heart disease
and hypercholesterolaemia (206),
chronic arrhythmia (207), colitis ulcer-
osa and Crohn’s disease (208), and
Glaucoma (114).
Regarding concomitant medication,
all purchased and reimbursed medica-
tions are recorded nationwide in the
Finnish Prescription Register (FPR)
and Finnish Registry for Reimbursed




ddd_index/). For each drug, reimburse-
ment-related factors, including the dis-
pensing date (date of purchase), the
WHO ATC code and the quantity dis-
pensed (amount in deﬁned daily doses),
were recorded as classiﬁed by WHO
(WHOCC 2012) (WHOCC- ATC/
DDD Index).
Details were obtained regarding the
drugs prescribed in the year before and
following the ﬁrst operation, including
statins (ATC code C10AA), insulins
(A10A), other diabetes drugs (A10B),
beta-blocking agents (C07) and
antithrombotic drugs (B01A). Aspirin
use could not be analysed, as this
medication is not reimbursed in Fin-
land. We assumed that the drug was
used at time of the ﬁrst surgery if the
purchase before surgery would cover
the operation date based on the infor-
mation of the DDD purchased. We
used only baseline usage of drugs as
covariates.
Mortality data were retrieved from
SF, where the vital status is collected
for all Finnish citizens into the Finnish
Causes of Death Register (Gissler &
Haukka 2004).
Vitreoretinal surgery
The surgical technique was the stan-
dard three-port 20-, 23- or 25-gauge
transconjunctival PPV (Constellation
Vision System, Alcon Laboratories,
Inc., Fort Worth, TX, USA), using a
valved microcannula (trocar) system
and a noncontact EIBOS viewing sys-
tem, with or without additional chan-
delier illumination. Our study
population included VR patients with
ﬁrst-performed operations coded with
frank vitrectomy (CKD91), vitrectomy
with retinal procedure [including
removal of membranes, use of perﬂu-
orocarbon if needed, endolaser, ﬂuid-
air exchange, with air, gas (SF6, C2F6,
C3F8) or silicone oil tamponade]
(CKD92), vitrectomy with encircling
SB or band (CKD93) and phacovitrec-
tomy (CKD94).
Follow-up time and end-points
The follow-up period commenced after
the ﬁrst operation. The primary
end-point event was the revitrectomy
during the postoperative follow-up
period due to redetachment (H33.0),
vitreous rehaemorrhage (H43.1),
endophthalmitis (H44.0), secondary/
recurrent pucker or unclosed macular
hole (H35.38).
Revitrectomy was deﬁned to be an
operation with codes CKD91, CKD92,
CKD93 or CKD94 of the same eye, and
the follow-up time for revitrectomy was
1 year. Only the ﬁrst revitrectomy was
taken into account. If there was no
revitrectomy in 1 year after start of
follow-up, censoring took place. Death
before 1 year after start of follow-up
was accounted as a censoring event.
Ethical considerations
This is a register-based study without
patient contact. The study protocol
was approved by the Ethics Commit-
tees of the Hjelt Institute, University
of Helsinki, and the Hospital District
of Helsinki and Uusimaa, Helsinki,
Finland.
Statistical analysis
We modelled incidence of resurgery
using Poisson regression models. Inci-
dence rate ratio (IRR) was calculated
using log link function and incidence
rate diﬀerences (IRD) with identity link
function (Boshuizen & Feskens 2010).
In both models, cumulated follow-up
time was taken into account. All anal-
yses were carried out separately for the
seven above-mentioned diagnostic sub-
groups. Hazard of re-operation was
modelled using Poisson regression with
splines.
We controlled for confounding
using background variables as model
covariates and also applied inverse
probability of treatment weighting
(IPTW) method (Hernan et al. 2000).
In IPTW, the propensity score (pre-
dicted probability of statin treatment
given baseline characteristics) was
used to generate patient-speciﬁc stabi-
lized weights that control for covariate
imbalances. The following variables
were used in construction of weights:
age, sex, BMI, year of surgery, type of
surgery, baseline usage of insulin,
other diabetes drug, antithrombotic
drugs and beta-blocker. All data anal-
yses were carried out using R language
(R Core Team 2016. Available at
https://www.R-project.org/).
Results
Baseline characteristics of our study
cohort (n = 5709) are summarized in
Table 1. Patients were operated as
inpatient hospitalization (42%), day
surgery (37.6%) and emergency cases
(20.1%). The gender distribution was
equal in our cohort. The mean dura-
tion of operation was 1.1 hr (SD
0.6 hr) in the whole cohort.
Systemic diseases in our study cohort
The most common systemic comor-
bidities of all VR patients (n = 5709)
were hypertension (n = 1278, 22.4%),
diabetes mellitus (n = 1014, 17.8%),
coronary artery disease (n = 518,
9.1%), connective tissue disease such
as rheumatoid arthritis (n = 203, 3.6%)
and psychiatric disease (n = 91, 1.6%).
Of the study patients, 8.1% (n = 465)
had glaucoma.
Of the whole patient cohort, 8.8%
(n = 504) received insulin therapy and
11.7% (n = 666) used oral antidiabet-
ics  insulin. Altogether 21% (n = 1198)
444
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Table 1. Baseline characteristics of study population.
Number
All No statin Statin
n = 5709 n = 4266 n = 1443
Mean SD NA Mean SD NA Mean SD NA
Age (y) 65.4 13.7 0 63.9 14.4 0 69.9 9.8 0
Height (cm) 170.1 10.5 199 170.3 10.7 144 169.5 9.7 55
Weight (kg) 77.2 16.6 216 76.3 16.6 154 79.8 16.5 62
BMI (kg/m2) 26.6 4.8 223 26.2 4.7 160 27.7 4.9 63
Duration of anaesthesia (h) 1.9 0.7 0 1.9 0.7 0 1.8 0.6 0
Duration of operation (h) 1.1 0.6 0 1.1 0.6 0 1.0 0.5 0
Gender
Male 2915 51% 2151 50% 764 53%
Female 2794 49% 2115 50% 679 47%
Systemic diseases
Diabetes mellitus
No 4695 82% 3705 87% 990 69%
Yes 1014 18% 561 13% 453 31%
Severe psychotic and other severe mental disorders
No 5618 98% 4194 98% 1424 99%
Yes 91 2% 72 2% 19 1%
Connective tissue diseases, rheumatoid arthritis and comparable diseases
No 5506 96% 4112 96% 1394 97%
Yes 203 4% 154 4% 49 3%
Chronic hypertension
No 4431 78% 3534 83% 897 62%
Yes 1278 22% 732 17% 546 38%
Chronic coronary heart disease
No 5191 91% 4083 96% 1108 77%
Yes 518 9% 183 4% 335 23%
Ocular comorbidity
Glaucoma
No 5244 92% 3929 92% 1315 91%
Yes 465 8% 337 8% 128 9%
Systemic medication at baseline
Insulin
No 5205 91% 3999 94% 1206 84%
Yes 504 9% 267 6% 237 16%
Oral antidiabetics
No 5043 88% 3957 93% 1086 75%
Yes 666 12% 309 7% 357 25%
Any beta-blocker
No 4511 79% 3620 85% 891 62%
Yes 1198 21% 646 15% 552 38%
Metoprolol
No 5477 96% 4149 97% 1328 92%
Yes 232 4% 117 3% 115 8%
Bisoprolol
No 4988 87% 3883 91% 1105 77%
Yes 721 13% 383 9% 338 23%
Any antithrombotic
No 5195 91% 4031 94% 1164 81%
Yes 514 9% 235 6% 279 19%
Warfarin
No 5400 95% 4103 96% 1297 90%
Yes 309 5% 163 4% 146 10%
Clopidogrel
No 5550 97% 4221 99% 1329 92%
Yes 159 3% 45 1% 114 8%
ASA Classiﬁcation
1 737 13% 723 17% 14 1%
2 1732 30% 1480 35% 252 17%
3 2401 42% 1443 34% 958 66%
4 159 3% 88 2% 71 5%
NA 680 12% 532 12% 148 10%
Diagnosis group
Retinal Detachment 1916 34% 1554 36% 362 25%
Pucker/MH 2207 39% 1569 37% 638 44%
445
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used beta-blockers (bisoprolol 12.6%
(n = 721) and metoprolol 4.1% (n =
232)), and9.1%(n = 514) hadantithrom-
botics (warfarin 5.4% (n = 309) and
clopidogrel 2.8% (n = 159)).
Statin medication in our study cohort
Among the whole cohort, the most
common medication used was statin
therapy (n = 1443, 25.3%), simvastatin
being the most commonly used statin
(n = 904, 15.8%), following atorvas-
tatin (n = 313, 5.5%) and rosuvastatin
(n = 130, 2.3%). The majority of statin
users (n = 1257, 87.1%) had been using
statin therapy longer than 6 months
before VR operation.
Statin was used in 362 of 1916 RRD
patients (18.9%), in 638 of 2207macular
hole or pucker patients (29%), in 137 of
400 vitreous haemorrhage patients
(34%) and in 29 of 120 lens subluxation
patients (24.2%).
Type of primary VR surgical procedure
Interestingly, frank vitrectomy was the
most common type of VR surgery
performed in our cohort (n = 2255;
39.4%). The vitrectomy with retinal
procedure comprised the second largest
group with 2017 cases (35.5%). Pha-
covitrectomy was performed in 1226
operations (21.5%). Only a minority of
patients underwent vitrectomy with an
encircling element (SB or encircling
band) (n = 211, 3.7%).
Of the vitrectomized (CKD91 oper-
ated) patients, 630 (27.9%) used statin
compared with 426 (20.1%) of patients
that underwent vitrectomy with retinal
procedure (CKD92 operation), 39
(18.5%) of patients with vitrectomy
and encircling SB or band (CKD93
operated) and 348 (28.4%) of patients
with phacovitrectomy (CKD94 oper-
ated).
Re-operation rate in the whole cohort
Altogether, re-operation was performed
in 10% of our cohort study eyes
(n = 5709). We observed 569 re-opera-
tions in 4556 person-years of follow-up
with 0.80 years mean follow-up time.
Females had lower re-operation rate
(10.6 per 100 person-years; 95%CI 9.3–
12.1) than males (14.3; 12.8–16.0), with
IRR 0.74 (0.63–0.88).
Of the 569 re-operated patients, 453
had no statin therapy as compared with
116 cases with statin therapy (70
patients with simvastatin, 22 atorvas-
tatin, 14 rosuvastatin and 10 other
statin). Median age at re-operation was
67 years (IQR 59–74). Simvastatin and
atorvastatin were evidently more bene-
ﬁcial than rosuvastatin regarding the re-
operation rate in our cohort (Fig. 2).
Incidence of revitrectomy was 5% in
eyes originally operated with frank vit-
rectomy (n = 119), 13% in eyes operated
with vitrectomy and retinal procedure
(n = 262), 40.3% in eyes with vitrectomy
and encircling SB or band (n = 85) and
8.4% in eyes with phacovitrectomy
(n = 103), respectively.
Hazard of re-operationmodelled with
Poisson regression in the whole cohort
(n = 5709) was highest approximately
1 month postoperatively (Fig. 3).
Re-operation rate differs between types of
surgical procedure performed and according
to main VR surgical indication
The rate of re-operations varied among
the main VR surgical study groups,
which displayed various incidence for
eyes re-operated: 15.9% in the RRD
group, 3.5% in the macular pucker/hole
group, 9.75% in the VH group, 8.3% in
the lens subluxation group and 13% in
the diabetic group. Generally, survival
from re-operation was best in frank
vitrectomy-operated eyes, followed by
phacovitrectomized eyes, eyes operated
with vitrectomy and retinal procedure,
and it was worst in eyes with vitrectomy
and encircling SB or band (Fig. 4).
RRD subgroup
Overall, RRD was the second most
frequent indication of VR surgery,
Table 1. (Continued)
Number
All No statin Statin
n = 5709 n = 4266 n = 1443
Mean SD NA Mean SD NA Mean SD NA
Vitreous haemorrhage 400 7% 263 6% 137 9%
Lens subluxation 120 2% 91 2% 29 2%
DR(PDR/DME) 184 3% 119 3% 65 5%
Vitreous opacities 52 1% 39 1% 13 1%
Other 830 15% 631 15% 199 14%
Operation type
CKD91 2255 39% 1625 38% 630 44%
CKD92 2017 35% 1591 37% 426 30%
CKD93 211 4% 172 4% 39 3%
CKD94 1226 21% 878 21% 348 24%
Operation mode
1. Inpatient 2399 42% 1794 42% 605 42%
2. Day surgery 2146 38% 1544 36% 602 42%
3. Emergency 1147 20% 912 21% 235 16%
5. Day surgery/Inpatient 14 0% 13 0% 1 0%
6. Policlinic 3 0% 3 0% 0 0%
BMI = body mass index, DME = diabetic macular oedema, DR = diabetic retinopathy, MH = macular hole, NA = not available, PDR = prolif-
erative DR.
Extended vitrectomy through pars plana (CKD91), combined vitrectomy and retinal procedure (CKD92), extended combined procedure on vitreous




performed in 1916 (34%) patients, with
305 re-operations with a rate of 0.20
(95% CI 0.18–0.23) per person-year.
Almost half of our RRD patients were
operated as emergency patients (48.7%)
and 81.6% of all RRD patients under-
went vitrectomy and retinal procedure
surgery, with vitrectomy and encircling
SB or band performed in 8.8%, pha-
covitrectomy in 6.6% and frank vitrec-
tomy in 3%.
The majority of patients operated
due to RRD were male (n = 1242,
64.8%), 17.3% had hypertension,
9.0% diabetes, 6.7% coronary artery
disease, 2.9% connective tissue disease
(rheumatoid arthritis) and 1.6% psy-
chiatric disease. The most common
concomitant ocular disease of RRD
patients was glaucoma (5.7%).
In the RRD group, 18.9% (n = 362)
used statin therapy (11.1% simvastatin,
4.3% atorvastatin, 2.1% rosuvastatin).
In general, RRD was the second most
common diagnosis (25%) among all
statin-treated patients (n = 1443). Note-
worthy, only 3.1%ofRRDpatientswere
on insulin therapy, while 15.6% used
beta-blocker and 6.2% antithrombotic
(3.4% warfarin, 2.1% clopidogrel).
Re-operation rate was lower in
statin-treated RRD eyes (n = 49) com-
pared with nonstatin-treated RRD eyes
(n = 256; Table 2) during our 6.5-year
study, with a rate of 16.8 per 100
person-years (95% CI 12.4–22.2).
After adjustment for baseline char-
acteristics, patients with RRD experi-
ence a greater beneﬁt from statin
therapy compared with RRD patients
without statin therapy (Table 3). Statin
treatment at the time of operation was
associated with lower risk of re-opera-
tion in patients with RRD according to
relative scale (IRR 0.72, 95% CI 0.53–
0.97), but not in absolute scale (IRD
0.01, 0.04 to 0.03). Furthermore,
according to cumulative incidence of
re-operation (Fig. 5), statin treatment
at the time of operation was associated
with lower risk of re-operation in
patients with RRD.
Main reasons for re-operation in the RRD
group
Of 305 re-operated RRD eyes, 236 were
operated due to redetachment and 34
due to secondary epiretinal membrane,
that is macular pucker or macular hole.
Five RRD-operated patients developed
postoperative endophthalmitis and
were re-operated. The other 30 eyes with
RRD were re-operated due to removal
of silicon oil that was not counted as a
re-operation. None of the patients who
developed endophthalmitis were dia-
betic or had preoperative antiplatelet
therapy. Interestingly, three of themhad
glaucoma with topical therapy and two
used simvastatin therapy.
Other subgroups in our cohort
In our cohort, the largest VR group
(31%) consisted of eyes operated due to

















Fig. 2. Incidence of re-operation modelled with Poisson regression in the whole cohort (n = 5709)
diﬀered according to statin compound.






























Fig. 3. Hazard of re-operation in retinal detachment and pucker/MH subgroups (N = 569) (95%
CI). Rug plot indicates timing of re-operations. Hazard curve and conﬁdence interval estimated
using Poisson regression model with splines.
















Fig. 4. Survival from re-operation according to vitreoretinal surgery procedure. Vitrectomy
through pars plana (CKD91, VIT), combined vitrectomy and retinal procedure (CKD92,
VITRET), combined procedure on vitreous body and retina including encircling scleral band
(CKD93; SBVIT) and combined phacoemulsiﬁcation and intraocular lens implantation together
with pars plana vitrectomy (CKD94; PhacoVIT).
447
Acta Ophthalmologica 2018
age-related VR eye diseases, macular
hole or pucker (n = 2207).Of those eyes,
81.4% (n = 1796) were operated as day
surgery cases (elective surgery). Of these
cases, 67.4% (n = 1487) underwent
frank vitrectomy surgery and 28.5%
(n = 629) combined phacovitrectomy.
Based on our analysis, the overall re-
operation rate was lowest in this group
(3.5%). Operation duration was also
shortest in this group, being compara-
ble with cases operated due to vitreous
opacities.
Altogether 638 patients (28.9%)
with macular hole or pucker were on
statin therapy. However, in this sub-
group, no beneﬁcial eﬀect of statin use
was observed regarding re-operation
rate (Table 2, Fig. 5).
Patients operated due to DR
(n = 184), vitreous haemorrhage (n =
400), lens subluxation (n = 120), vitre-
ous opacities (n = 52) or other VR
reasons (n = 830) were analysed
accordingly, but in these subgroups,
no beneﬁcial eﬀect of statin use was
found in regard to re-operation rate
(Table 2).
Discussion
Our cohort study demonstrated that
statin treatment was associated with a
relatively lower incidence of revitrec-
tomy by 28% in the group of patients
operated due to retinal detachment.
Currently, there is no evidence-based
data supporting our ﬁndings for statin
use in RRD surgery, with no random-
ized controlled study, systematic
reviews, or Cochrane database data
related to this clinically important topic
(PubMed search). Interestingly, no
association between statin therapy
and lower re-operation rate was found
in other studied VR indication groups
in our epidemiologic study.
Previously, statin therapy has been
shown to reduce the rate of major
coronary heart disease events by 25%
[Cholesterol Treatment Trialists’ (CTT)
Collaborators 2008]. In Finland, statins
are available by prescription only, and
adherence to statin therapy is known to
be better in patients with a history of
cardiovascular disease or diabetes, and
among middle-aged and older patients
(Halava et al. 2016). Simvastatin was
introduced to the Finnish market in
1992, atorvastatin in 1998 and rosuvas-
tatin in 2003. Simvastatin has also been
the most commonly used statin in Fin-
land since 1997, being chosen for 39%of
new statin users in 1998 as compared
with 18% with atorvastatin (Halava
et al. 2009). However, 12% of statin
initiators are known to discontinue
therapy due to side-eﬀects (Halava et al.
2016).
Among all VR surgical indications,
RRD is the most feared, potentially
sight-threatening VR disease and oph-
thalmic emergency (Feltgen & Walter
2014). In our study, the re-operation
rate of all RRD patients was 15.9%,
being in accordance with previous
studies. Observational studies have
reported the re-operation rate to be
13.3% for PPV, 12.3% for SB, 14.5%
for combined PPV and SB surgery, and
around 12–13% for emergency and
routine patients (Koch et al. 2012;
Jackson et al. 2014).
Fibrosis formation is associated with
various posterior segment eye diseases
Table 2. Number and rate of (per 100 person-years) re-operation for each vitreoretinal surgical diagnosis subgroup. 95% conﬁdence interval (CI)
based on Poisson distribution.
Vitreoretinal surgery indication
No statin Statin
p-years (1/100) Events Rate 95% CI p-years (1/100) Events Rate 95% CI
Retinal Detachment 12.18 256 21.0 18.5 23.8 2.92 49 16.8 12.4 22.2
Pucker/MH 12.83 61 4.8 3.6 6.1 5.28 17 3.2 1.9 5.2
Vitreous haemorrhage 2.13 24 11.3 7.2 16.8 1.09 15 13.8 7.7 22.8
Lens subluxation 0.69 7 10.1 4.1 20.9 0.25 3 12.2 2.5 35.6
DR (PDR/DME) 0.86 18 21.0 12.4 33.1 0.50 6 12.0 4.4 26.2
Vitreous opacities 0.33 3 9.0 1.9 26.3 0.10 0 0.0 0.0 35.4
Other 4.91 84 17.1 13.6 21.2 1.48 26 17.6 11.5 25.7
DME = diabetic macular oedema, DR = diabetic retinopathy, MH = macular hole, PDR = proliferative DR.
Table 3. Comparing statin to no statin group. Multivariate models adjusted with sex, age, duration of operation, type of procedure, insulin usage,
oral antidiabetic drug usage, antihrombotic drug usage and beta-blocker usage, and diagnosis subgroup as covariates, and IPWT weighted.
No statin Statin
Vitreoretinal surgery indication
IRR, univariate IRD, univariate IRR, IPWT model IRD, IPWT model
IRR 95% CI IRD 95% CI IRR 95% CI IRD 95% CI
Retinal Detachment 0.80 0.59 1.08 4.25 9.60 1.11 0.72 0.53 0.97 0.58 4.30 3.15
Pucker/MH 0.68 0.34 1.16 1.54 3.48 0.40 0.86 0.52 1.44 0.05 2.04 2.14
Vitreous haemorrhage 1.23 0.64 2.34 2.54 5.78 10.86 1.84 0.99 3.42 7.54 2.11 17.19
Lens subluxation 1.20 0.31 4.64 2.04 13.67 17.75 0.15 0.02 1.47 0.16 3.89 4.21
DR (PDR/DME) 0.57 0.23 1.45 8.92 22.57 4.72 0.33 0.08 1.28 6.52 19.41 6.37
Vitreous opacities NA NA NA 8.99 19.16 1.18 NA NA NA 0.71 12.50 13.92
Other 1.03 0.66 1.59 0.44 7.24 8.11 1.38 0.88 2.15 6.72 1.15 14.58
All combined 0.75 0.61 0.92 3.37 5.56 1.18 0.94 0.76 1.15 0.22 1.81 1.36
DME = diabetic macular oedema, DR = diabetic retinopathy, IRD = Incidence rate diﬀerence for 100 person-years, IRR = incidence rate ratio,
MH = macular hole, NA = not available, PDR = proliferative DR.
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including vascular (DR), nonvascular
(RRD) and neurodegenerative (macu-
lar pucker/hole) eye diseases. Even
after initial successful primary RRD
surgery, ﬁbrosis or PVR is the most
frequent and severe complication and a
major cause of failure after RRD
surgery, with an incidence occurring
in 4–34% of operated RRD eyes in
prospective studies (Heimann et al.
2007; Kawahara et al. 2008; Pastor
et al. 2016). Ischaemia, hypoxia and
(neuro)inﬂammation are considered to
be the major components of PVR
formation after RRD surgery, ampli-
ﬁed by a genetic pro-inﬂammatory
proﬁle (Garweg et al. 2013; Rojas et al.
2013). To improve the surgical out-
come of eyes with RRD, modiﬁcation
of the inﬂammatory, cell proliferation,
tissue remodelling and scar tissue-
related processes involved in PVR is
of great importance (Kawahara et al.
2008; Garweg et al. 2013; Pennock
et al. 2013; Li et al. 2014). According
to our cohort study, statin treatment
could be associated with a decreased
risk of PVR ﬁbrosis in our RRD
eyes and therefore reduce the risk of
re-operation.
Herein, we analysed all eyes that
underwent vitrectomy procedure in our
hospital during 2008–2014. In our
study, the RRD eyes operated with
conventional SB surgery without vit-
rectomy were not included or analysed.
Rates of RRD patients undergoing
vitrectomy have shown a more than
10-fold increase from 1985 to 2004 in
UK (El-Amir et al. 2009), and in our
centre, vitrectomy has become the pre-
ferred surgical technique for primary
RRD (Sahanne et al. 2017), being in
line with other latest studies (Poulsen
et al. 2016; Haugstad et al. 2017).
In a recent paper, the most common
systemic comorbidities of VR surgical
patients were hypertension (53%), dia-
betes mellitus (37%) and coronary
artery disease (18%) (Shalwala et al.
2015). In our study, however, these
systemic diseases were less common
among the patients. Shalwala et al.
(2015) also reported signiﬁcantly
increased incidence of postoperative
systemic adverse events after VR sur-
gery in patients with coronary artery
disease, asthma, chronic renal disease
or in patients operated under general
anaesthesia. Unfortunately, in our
study, the documented register data
did not allow us to analyse systemic
adverse events among the cohort.
As regards the other VR surgical
groups studied in our cohort, we found
no beneﬁcial eﬀect associated with
statin use. One reason might be that
in the majority of other VR groups,
less than 10% of operated patients
received statin therapy. The only
exception was patients operated due
to MH/pucker (n = 2207), of which
one-third were prescribed statin ther-
apy well before surgery, without statis-
tically signiﬁcant beneﬁcial eﬀect of
statin being found in the re-operation
rate. The majority of these MH/pucker
patients underwent elective day sur-
gery, either frank vitrectomy or com-
bined phacovitrectomy, that also are
generally considered relatively safe sur-
gical procedures with lower rate of
adverse outcome compared with eyes
with more complex VR pathology.
Perhaps the additional beneﬁt of statin
was too small to be found in the
statistical analysis. Of note, in our
previous paper, we found that systemic
statin therapy might have a favourable
eﬀect on intravitreal factors involved in
ﬁbroproliferation in ageing human
pucker eyes (Tuuminen & Loukovaara
2016).
With ageing population, the num-
ber of patients using anticoagulant/
antiplatelet treatment has increased in
recent years worldwide (Grzybowski
et al. 2015; Kong & Khan 2015). Con-
comitant use of novel oral anticoagu-
lants (clopidogrel) or old warfarin and
statin is common in the secondary
prevention of cardiovascular events,
representing 4.9% of study eyes in
our VR surgical cohort. According to
our analysis, VR surgery of eyes of
patients who were under warfarin or
clopidogrel therapy was not associated
with increased risk of re-operations
after primary surgery. Therefore, our
ﬁndings are in agreement with previous
studies, suggesting that patients with
anticoagulant may enter VR surgery
safely while maintaining their antico-
agulant therapy (Ryan et al. 2013), as
long as their INR values are within the
therapeutic range 2–3. Actually, revit-
rectomy rate in our study setting was
lower in patients undergoing VR sur-
gery using clopidogrel than without.
However, patient population undergo-
ing VR surgery using clopidogrel was
small in our study.
Of the three statins used by our
cohort (simvastatin, atorvastatin, rosu-
vastatin), only simvastatin seemed to
be associated with the incidence of
lower revitrectomy rate. Statin com-
pounds have distinct pharmacokinetic
and pharmacodynamic properties that
aﬀect their overall eﬃcacy, safety and
potential non-LDL-cholesterol action
(Mason et al. 2005). Atorvastatin and
simvastatin are both lipophilic agents,
whereas rosuvastatin is not. Lipophilic-
ity may inﬂuence the eﬃcacy of the
statin compound and has an eﬀect on
the pleiotropic eﬀects of statins such as
cell function, coagulation and inﬂam-
mation. Atorvastatin/simvastatin may
have a greater eﬀect on inﬂammatory
pathways compared with rosuvastatin
and explain our results (Mason et al.











Time since operation (days)
H33.0, no statin
H33.0, statin
H35.38 or H35.37, no statin
H35.38 or H35.37, statin
Fig. 5. Cumulative incidence of re-operations among the two most frequent vitreoretinal surgery
diagnosis groups (H33.0 = retinal detachment and H35.38/H35.37/H35.39 = macular pucker
and hole) according to baseline statin usage. Third edition of the Finnish version of the
International Statistical Classiﬁcation of Diseases and Related Health Problems (http://urn.ﬁ/
URN:NBN:ﬁ-fe201205085423) was used after February 2011. In this updated version of the ICD
coding classiﬁcation, macular hole (H35.37) and macular pucker (H35.38) got their own ICD
codes in Finland instead of both being recorded as H35.39.
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2005). Interpreting the study results, we
should, however, bear in mind that the
reasons for prescribing diﬀerent types
of statins to patients are related to
systemic diseases, and therefore, we
may not draw strong conclusions
regarding the type of statin compound.
Statin therapy was initiated well
before, for the majority of statin users
(87.1%) longer than 6 months before,
the index VR operation was per-
formed, most probably exerting the
full pleiotropic eﬀect on the operated
eye (Barakat et al. 2016). More thor-
ough analysis of this pharmacologic
aspect cannot be performed based on
our register-based study setting.
A clear increase in VR surgical
activity in our VR unit took place
between 2008 and 2014, which was the
period when operations were carried
out. The total volume of operated VR
cases was higher during 2011–2014
than during 2008–2010. This trend
probably reﬂects the development of
surgical instrumentation, technique
and shorter operational times. The
major limitation of our study was its
register-based design with somewhat
robust data collection and a limited 1-
year postoperative follow-up. There-
fore, baseline ophthalmic data (such as
degree of PVR ﬁbrosis), intra-operative
complications arising from surgery,
and surgical procedure-related charac-
teristics (intravitreal dyes, type of gas/
silicone oil) could not be taken into
account in the analysis. This kind of
very accurate eye-related analysis is
beyond the scope of an epidemiological
register-based study without pre-
planned structural databases. By
improving the present structural data-
bases at a national level, however,
Finland and the other Nordic countries
could form a proper environment for
top-level internationally competitive
medical research in the future. Prospec-
tive clinical surgical studies are thus
warranted to address these features in
the future. Another major limitation
was that the operations were not per-
formed by the same VR surgeon. It is
also commonly known that choice of
the VR surgical method varies between
VR surgeons and centres. However, it
is not probable that there is an associ-
ation between surgeon and the eﬀect of
statin. Thus, potential diﬀerences
between surgeons probably did not
cause any bias on statin eﬀect. In
observational studies, it is possible that
there are confounding factors con-
nected to statin use. We controlled for
this confounding using background
variables as model covariates and also
applied IPTW method. Despite these
attempts, it is possible that some bias
remains.
The remaining important issues that
are not addressed in our cohort obser-
vational study are as follows. To whom
and what age groups should statin
therapy be given and how is statin
therapy best used as an adjuvant agent
in prevention of re-operations after
RRD surgery? Should we perhaps start
all diagnosed RRD patients with sta-
tin? And if so, what would be the
optimal dose of statin therapy, timing
of medication and form of delivery
(oral, nanomicelles, simvastatin-coated
implant, intravitreal single dose statin
injection)? Based on animal studies, use
of statin should not hinder retinal
function, but surely, further ultrastruc-
tural human eye studies are also war-
ranted (ILM, nerve ﬁbre layer,
ganglion cell) to address this issue
more properly. Future studies of ligus-
trazine implant (Zhang et al. 2015) and
resveratrol (Ishikawa et al. 2015) might
also address whether these novel agents
could be beneﬁcial in prevention of
PVR. As a whole, an assessment of
pathogenesis of PVR is needed to help
development of novel eﬀective thera-
peutic approaches, especially treatment
targeting epithelial to mesenchymal
transition of retinal pigment epithelial
cells in the pathogenesis of PVR
(Ishikawa et al. 2015; Pastor et al.
2016). In Finland, our population is
homogenous and our study results
might not reﬂect the re-operation rate
in RRD eyes operated in genetically
more heterogenous study populations
and backgrounds.
To conclude, use of statin treatment
was associated with 28% lower risk of
revitrectomy in the group of patients
operated due to RRD in our real-world
cohort setting. Therefore, our study
highlights the idea of prescribing statin,
especially simvastatin, treatment in the
future, for surgical RRD patients.
However, before we actually can rec-
ommend the prescription of any statin
therapy to RRD patients that are to be
operated, our intriguing preliminary
ﬁndings based on an epidemiologic
single-centre study merit conﬁrmation
by other more in-depth studies. At the
population level, a clear beneﬁt has
been observed in favour of statins in
general, and currently statin therapy is
considered safe, with few side-eﬀects.
In fact, in USA, statins are the most
commonly prescribed medication class
and it has been estimated that half of
the population aged 40–75 would ben-
eﬁt from statin therapy, as statins are
known to decrease incidence of coro-
nary heart disease (Taylor et al. 2013;
Kantor et al. 2015). In practice, one
major limitation is the compliance and
adherence to statin therapy. It is gen-
erally known that some patients are
afraid of potential side-eﬀects (rhab-
domyolysis), and unwilling to use
statins. Currently, there is very limited
data available regarding the eﬃcacy of
statin treatment in reducing adverse
postoperative VR surgical outcomes,
and therefore, further observational
studies and randomized clinical trials
studies are highly warranted. Notewor-
thy, early perioperative exposure to
statin was very recently shown to be
associated with a signiﬁcant reduction
in several surgical complications,
including neurosurgery and orthopae-
dic (London et al. 2016). As VR
surgery was not covered and analysed
in that study, our preliminary data are
needed to cover the full spectrum of
diﬀerent procedures more thoroughly.
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